Disease Progression: Clinical Trials

227 completed, 114 unknown, 108 recruiting, 49 not yet recruiting. 113 Phase 2, 107 Not applicable, 46 Phase 1, 40 Phase 3, 19 Phase 4.

By phase and status

Phase	Trials	Status
Phase 2	113	Completed 30, Unknown 22, Recruiting 19, Not yet recruiting 14, Terminated 12, Withdrawn 10, Active not recruiting 3, Suspended 3
Not applicable	107	Completed 34, Recruiting 28, Unknown 22, Not yet recruiting 10, Active not recruiting 5, Terminated 5, Withdrawn 3
Phase 1	46	Completed 16, Recruiting 8, Terminated 5, Active not recruiting 4, Unknown 4, Withdrawn 4, Not yet recruiting 3, Suspended 2
Phase 3	40	Completed 21, Recruiting 6, Active not recruiting 5, Unknown 4, Terminated 3, Withdrawn 1
Phase 4	19	Completed 9, Unknown 6, Recruiting 2, Terminated 2
Early Phase 1	2	Active not recruiting 1, Recruiting 1

Follow Disease Progression: new trials by email Literature Review of Disease Progression trials Research Report on Disease Progression

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Effectiveness of Silver Nitrate Cauterization vs Conservative Management in Tympanic Membrane Perforation Closure 50% Silver Nitrate Cauterization - Tympanic Membrane Perforation	Not applicable	Not yet recruiting	Muhammad Ali Javed	56	2027-01-01	2026-09-22
Symptom Trajectory Approaches to Research Health surveys - Advanced Cancer, Metastatic Disease		Not yet recruiting	University of Wisconsin, Madison	228	2026-12-01	2026-09-04
Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis Therapeutic Plasma Exchange, Rituximab, Intravenous immunoglobulin - Idiopathic Pulmonary Fibrosis	Phase 2	Not yet recruiting	University of Alabama at Birmingham	52	2026-12-01	2026-10-20
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) azacytidine, carboplatin, paclitaxel - Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung	Phase 1 / Phase 2	Suspended	National Cancer Institute (NCI)	60	2026-11-04	2026-10-30
MAGICS - Multi-Agent Generative AI in Clinical Simulation for Clinical Deterioration Training Generative AI-integrated Blended Simulation, High Fidelity Simulation - Clinical Reasoning in Nursing Education, Virtual Simulation	Not applicable	Not yet recruiting	National University of Singapore	200	2026-10-12	2026-10-21
Colchicine Effect on Amyotrophic Lateral Sclerosis Patients Colchicine 0.5 MG Oral Tablet, Placebo Oral Tablet - Amyotrophic Lateral Sclerosis	Phase 2	Not yet recruiting	Azienda Ospedaliero-Universitaria di Modena	87	2026-10-01	2026-09-10
BLinatumomab and iNKT in Relapsed B-Cell ALL Invariant Natural Killer T Cell Therapy - B-Cell ALL, ALL (Acute B-Lymphoblastic Leukemia)	Phase 1	Not yet recruiting	UNC Lineberger Comprehensive Cancer Center	13	2026-10-01	2026-10-09
SHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER2-Positive Early Breast Cancer After Pathologic Complete Response SHR-A1811, Trastuzumab, Pertuzumab - HER2-positive Breast Cancer, Early Breast Cancer (EBC)	Phase 2	Not yet recruiting	Fudan University	358	2026-10-01	2026-10-02
Hospital-Onset Sepsis Systematic Detection and Structured Interventions Algorithm-triggered sepsis alert with structured critical care team activation - Sepsis, Deterioration, Clinical	Not applicable	Not yet recruiting	Patricks Lyons	3700	2026-10-01	2026-09-04
Surgery After Verifying Existing Disease in Locally Advanced Operable Lung Cancer: A Pilot Study Observation without surgery, Standard-of-care surgery - Non-Small Cell Lung Cancer, Immunotherapy	Phase 1	Not yet recruiting	Centre hospitalier de l'Université de Montréal (CHUM)	14	2026-10-01	2026-08-14
Perioperative Adebrelimab for Locally Advanced Cervical Cancer Adebrelimab, Paclitaxel, Cisplatin - Locally Advanced Cervical Cancer	Phase 2	Not yet recruiting	Anhui Provincial Hospital	35	2026-10-01	2026-09-10
The Orientation Intervention to Rapid Response Teams (ORIENT-RRT) Study: A Quasi-Experimental Study Orientation day with rapid response nurse - Deterioration, Clinical	Not applicable	Recruiting	University of Colorado, Denver	300	2026-09-28	2026-10-27
Node-Sparing Short-Course Radiotherapy (25 Gy/5 Fractions) Combined With Chemoimmunotherapy as Neoadjuvant Treatment for Locally Advanced Esophageal Squamous Cell Carcinoma：A Prospective Single-Arm, Phase II Study Neoadjuvant SCRT + Camrelizumab + Nab-Paclitaxel/Carboplatin - ESCC	Phase 2	Recruiting	Sixth Affiliated Hospital, Sun Yat-sen University	33	2026-09-10	2026-09-09
Multimodal Physiologic State Intelligence Study OMNIPHYS Multimodal Ultrasound Imaging System - Heart Failure, Cardiomyopathies		Enrolling by invitation	Truway Health, Inc.	25000	2026-09-02	2026-09-10
Cognitive Outcomes in BAD-related Stroke END exposure - Branch Atheromatous Disease, Cognitive		Not yet recruiting	Peking Union Medical College Hospital	60	2026-09-01	2026-08-12
Multimodal Digital Biomarker Prediction of Acute Clinical Deterioration Multimodal Digital Biomarker Monitoring - Acute Disease, Disease Progression		Enrolling by invitation	Truway Health, Inc.	10000	2026-09-01	2026-09-14
Supervised Exercise During Neoadjuvant Chemotherapy for Breast Cancer Supervised exercise - Breast Cancer Early Stage Breast Cancer (Stage 1-3), Breast Neoplasm Malignant Female	Not applicable	Not yet recruiting	King Hamad University Hospital, Bahrain	80	2026-09-01	2026-08-13
Sacituzumab Tirumotecan in Pts w/ NEPC After Progression on Prior Chemotherapy Sacituzumab Tirumotecan - Prostate Cancer, Neuroendocrine Prostate Cancer (NEPC)	Phase 2	Not yet recruiting	Virginia Commonwealth University	20	2026-08-31	2026-08-24
Penpulimab Combined With Chemotherapy for Patients With Locally Advanced Hypopharyngeal Carcinoma Finotonlimab, Nab-paclitaxel, carboplatin - Head & Neck Cancer	Phase 2	Not yet recruiting	Tang-Du Hospital	15	2026-08-23	2026-08-07
Clinical Prediction Model for Disease Progression in Primary Membranous Nephropathy Membranous Nephropathy, Nephrotic Syndrome		Not yet recruiting	Assiut University	128	2026-08-20	2026-09-02

Showing 20 of 589. Sign in to see all of them.

Narrower conditions

Pathologic Complete Response (138)  ·  Breast Neoplasms (47)  ·  Clinical Deterioration (47)  ·  Recurrence (35)  ·  HIV Infections (23)  ·  Rectal Neoplasms (22)  ·  Carcinoma, Non-Small-Cell Lung (21)  ·  Neoplasms (20)  ·  Parkinson Disease (20)  ·  Urinary Bladder Neoplasms (17)  ·  Leukemia, Myeloid, Acute (16)  ·  Neoplasm Metastasis (15)  ·  Multiple Sclerosis (14)  ·  Pulmonary Disease, Chronic Obstructive (14)

Broader conditions

Pathologic Processes (589)  ·  Pathological Conditions, Signs and Symptoms (588)  ·  Disease Attributes (587)  ·  Neoplasms (242)  ·  Neoplasms by Site (190)  ·  Neoplasms by Histologic Type (123)  ·  Urogenital Diseases (108)  ·  Nervous System Diseases (93)  ·  Immune System Diseases (88)  ·  Respiratory Tract Diseases (86)  ·  Lung Diseases (80)  ·  Female Urogenital Diseases and Pregnancy Complications (74)  ·  Female Urogenital Diseases (69)  ·  Infections (66)

Interventions

Carboplatin (14)  ·  Cyclophosphamide (8)  ·  Paclitaxel (8)  ·  Cisplatin (7)  ·  Trastuzumab (7)  ·  pembrolizumab (7)  ·  Bortezomib (6)  ·  Dexamethasone (6)  ·  130-nm albumin-bound paclitaxel (5)  ·  Docetaxel (5)  ·  Drug Therapy (5)  ·  Fluorouracil (5)  ·  Gemcitabine (5)  ·  Neoadjuvant Therapy (5)  ·  Oxaliplatin (5)

Sponsors

National Cancer Institute (NCI) (12)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (12)  ·  Assistance Publique - Hôpitaux de Paris (9)  ·  M.D. Anderson Cancer Center (7)  ·  Peking Union Medical College Hospital (7)  ·  Sixth Affiliated Hospital, Sun Yat-sen University (7)  ·  Peking University People's Hospital (6)  ·  Radboud University Medical Center (6)  ·  AstraZeneca (5)  ·  Fudan University (5)  ·  Mansoura University (5)  ·  Massachusetts General Hospital (5)  ·  University of Zurich (5)  ·  Ain Shams University (4)  ·  Heidelberg University (4)

Countries

United States (160)  ·  China (103)  ·  France (50)  ·  Germany (43)  ·  Italy (35)  ·  Spain (30)  ·  United Kingdom (29)  ·  Netherlands (28)  ·  Denmark (22)  ·  Canada (20)  ·  Turkey (Türkiye) (19)  ·  Belgium (17)  ·  Poland (16)  ·  Austria (15)  ·  Brazil (14)

Top investigators

Zhenzhen Liu (4)  ·  Bastiaan R Bloem, MD, PhD (3)  ·  Talant M Sooronbaev, MD (3)  ·  Xiangbo Wan, MD, PhD (3)  ·  Zhenyu Liu, M.D. (3)  ·  Alon Harris, PhD (2)  ·  Amr A Elsawy (2)  ·  Antonio Lambiase, MD (2)  ·  Emilie Sigvardt, MD (2)  ·  Frank Van Der Aa, MD, PhD (2)  ·  Franz Schaefer, MD (2)

Results publications

PMID 28476882, PMID 38740994, PMID 10588596, PMID 12091180, PMID 12917227, PMID 14630977, PMID 14744931, PMID 15002082, PMID 15183474, PMID 15206062, PMID 15253732, PMID 15480138, PMID 15586136, PMID 15647341, PMID 15772249, PMID 16093916, PMID 16192247, PMID 16192248, PMID 16769940, PMID 16951642, PMID 16966687, PMID 17216857, PMID 18506712, PMID 18550610, PMID 18621575, PMID 18703788, PMID 19008157, PMID 19194318, PMID 19299237, PMID 19440326, PMID 19692142, PMID 19828532, PMID 19880262, PMID 20009882, PMID 20211870, PMID 20237308, PMID 20471236, PMID 20617176, PMID 20637974, PMID 20697104, PMID 20812949, PMID 20844049, PMID 20855414, PMID 20876174, PMID 21126955, PMID 21146205, PMID 21297946, PMID 21514629, PMID 21796368, PMID 21865400

NIH funding

2023 (3), 2025 (3), 2009 (2), 2016 (2), 2018 (2), U01HL069294 (2), 2005 (1), 2015 (1), 2017 (1), 2019 (1), K23EY022659 (1), M01RR000030 (1), M01RR000032 (1), M01RR000039 (1), M01RR000044 (1)